TD Cowen Keeps Their Buy Rating on Nautilus Biotechnolgy (NAUT)
Goldman Sachs Reaffirms Their Hold Rating on Nautilus Biotechnolgy (NAUT)
Morgan Stanley Reiterates Equal-Weight on Nautilus Biotechnology, Maintains $6 Price Target
Nautilus Biotechnology Analyst Ratings
Nautilus Group (NLS) Initiated With a Hold at Craig-Hallum
Craig-Hallum Keeps Their Buy Rating on Nautilus Group (NLS)
Nautilus Analyst Ratings
Truist Securities Cuts Nautilus' Price Target to $4 From $5, Maintains Buy Rating
Nautilus Analyst Ratings
Truist Securities Maintains Buy on Nautilus, Lowers Price Target to $4
Goldman Sachs Halves Price Target on Nautilus Biotechnology to $2 From $4 Amid Product Launch Delay; Neutral Rating Kept
Nautilus Biotechnolgy (NAUT) Gets a Hold Rating from Goldman Sachs
Morgan Stanley Lowers Nautilus Biotechnology's Price Target to $6 From $8, Maintains Equalweight Rating
Nautilus Biotechnolgy Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Nautilus Biotechnology, Lowers Price Target to $6
Nautilus Biotechnolgy Is Maintained at Neutral by Goldman Sachs
Nautilus Biotechnology analyst ratings
Goldman Sachs Maintains Neutral on Nautilus Biotechnology, Lowers Price Target to $2
Goldman Sachs Reaffirms Their Hold Rating on Nautilus Biotechnolgy (NAUT)
Goldman Sachs Adjusts Nautilus Biotechnology's Price Target to $4 from $5, Keeps Neutral Rating
No Data
No Data